Memorial Day! 45% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

Cidara Therapeutics Earnings Calls

Q1 2025 Beat
-$1.66 (69.54%)
Release date May 08, 2025
EPS estimate -$5.45
EPS actual -$1.66
EPS Surprise 69.54%
Revenue estimate -
Revenue actual -
Q4 2024 Missed
-$5.38 (-1.89%)
Release date Mar 06, 2025
EPS estimate -$5.28
EPS actual -$5.38
EPS Surprise -1.89%
Revenue estimate 240K
Revenue actual -
Q3 2024 Beat
-$2.38 (54.41%)
Release date Nov 07, 2024
EPS estimate -$5.22
EPS actual -$2.38
EPS Surprise 54.41%
Revenue estimate 400K
Revenue actual -
Q2 2024 Beat
-$2.05 (47.97%)
Release date Aug 13, 2024
EPS estimate -$3.94
EPS actual -$2.05
EPS Surprise 47.97%
Revenue estimate 4.7M
Revenue actual 302K
Revenue Surprise -93.57%

Last 4 Quarters for Cidara Therapeutics

Below you can see how CDTX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 13, 2024
Fiscal end date Jun 30, 2024
Price on release $12.15
EPS estimate -$3.94
EPS actual -$2.05
EPS surprise 47.97%
Date Price
Aug 07, 2024 $11.29
Aug 08, 2024 $11.59
Aug 09, 2024 $11.81
Aug 12, 2024 $11.73
Aug 13, 2024 $12.15
Aug 14, 2024 $12.86
Aug 15, 2024 $12.64
Aug 16, 2024 $12.79
Aug 19, 2024 $12.96
4 days before 7.62%
4 days after 6.67%
On release day 5.84%
Change in period 14.79%
Q3 2024 Beat
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $13.11
EPS estimate -$5.22
EPS actual -$2.38
EPS surprise 54.41%
Date Price
Nov 01, 2024 $13.09
Nov 04, 2024 $13.03
Nov 05, 2024 $13.26
Nov 06, 2024 $13.26
Nov 07, 2024 $13.11
Nov 08, 2024 $13.50
Nov 11, 2024 $13.35
Nov 12, 2024 $13.45
Nov 13, 2024 $13.90
4 days before 0.153%
4 days after 6.03%
On release day 2.97%
Change in period 6.19%
Q4 2024 Missed
Release date Mar 06, 2025
Fiscal end date Dec 31, 2024
Price on release $23.61
EPS estimate -$5.28
EPS actual -$5.38
EPS surprise -1.89%
Date Price
Feb 28, 2025 $24.90
Mar 03, 2025 $23.05
Mar 04, 2025 $23.16
Mar 05, 2025 $23.50
Mar 06, 2025 $23.61
Mar 07, 2025 $23.66
Mar 10, 2025 $22.39
Mar 11, 2025 $21.00
Mar 12, 2025 $23.00
4 days before -5.18%
4 days after -2.58%
On release day 0.212%
Change in period -7.63%
Q1 2025 Beat
Release date May 08, 2025
Fiscal end date Mar 31, 2025
Price on release $19.15
EPS estimate -$5.45
EPS actual -$1.66
EPS surprise 69.54%
Date Price
May 02, 2025 $21.69
May 05, 2025 $21.50
May 06, 2025 $19.70
May 07, 2025 $18.98
May 08, 2025 $19.15
May 09, 2025 $18.63
May 12, 2025 $19.43
May 13, 2025 $19.36
May 14, 2025 $19.31
4 days before -11.71%
4 days after 0.81%
On release day -2.72%
Change in period -11.00%

Cidara Therapeutics Earnings Call Transcript Summary of Q1 2025

Summary of Cidara Therapeutics Q1 2025 Earnings Call

Here's a summary of the key points from the Cidara Therapeutics Q1 2025 earnings call that investors should know:

  • Introduction of CD388

    Cidara's lead asset, CD388, is a novel antiviral drug for the prevention of influenza, designed to have universal activity against all strains, including high pathogenicity strains like H5N1. CD388 combines the antiviral zanamivir with a human antibody fragment to enhance efficacy and prolong its half-life, allowing for potentially once-per-season dosing.

  • Clinical Trial Updates

    The NAVIGATE Phase 2b study, which evaluates CD388 across three dosage groups (150 mg, 300 mg, and 450 mg) versus a placebo in 5,041 subjects, has completed dosing. Primary analysis results are expected to be announced by June 2025. Discussions with the FDA regarding the possibility of evaluating statistical significance in the study are ongoing due to the severity of the 2025 flu season.

  • Target Population Focus

    The initial target for CD388 is high-risk, comorbid, and immune-compromised patients, who are disproportionately affected by influenza. This population has significantly higher hospitalization and death rates and is under-served by existing treatments.

  • Market Opportunity and Pricing

    While historical estimates suggest a potential addressable market of around 20 million patients, the company sees opportunities to broaden this scope beyond severely affected individuals to include those with moderate conditions. Pricing discussions indicate potential for a value-based pricing approach substantially above previously modeled figures of $180-$200.

  • R&D Day on May 22

    A detailed R&D Day is scheduled for May 22, 2025, where more information on the ongoing clinical trials, data, regulatory discussions, and market needs will be shared.

  • Complementarity with Vaccines

    CD388 acts on a different target (neuraminidase) than traditional vaccines (which target hemagglutinin), implying potential complementarity rather than direct competition, especially in patients who are not adequately protected by vaccines.

  • Forward-Looking Statements

    As a non-revenue-generating company, Cidara cautions investors about forward-looking statements and uncertainties that may affect future results and timelines.

Overall, investors should monitor the upcoming results from the NAVIGATE study and insights from the R&D day for indications of CD388's market potential and regulatory path forward.

Cidara Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for CDTX?
Cidara Therapeutics (CDTX) has scheduled its earnings report for Aug 11, 2025 after the markets close.

What is the CDTX price-to-earnings (P/E) ratio?
CDTX P/E ratio as of May 23, 2025 (TTM) is -1.90.

What is the CDTX EPS forecast?
The forecasted EPS (Earnings Per Share) for Cidara Therapeutics (CDTX) for the first fiscal quarter 2025 is -$1.86.

What are Cidara Therapeutics's retained earnings?
On its balance sheet, Cidara Therapeutics reported retained earnings of $0 for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CIDARA THERAPEUTICS
Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...
GOLDEN STAR
Ticker Change Signal Date
UAA
$5.84
14.55% May 09
HBM
$7.41
18.89% May 05
PODD
$257.01
25.04% May 02
GT
$9.14
19.80% Mar 21
O
ODD
$44.71
55.78% Mar 13

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE